• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤浸润性CD8 T细胞和巨噬细胞的存在与葡萄膜黑色素瘤肝转移患者接受孤立性肝灌注治疗后的总生存期延长相关。

Presence of tumor-infiltrating CD8 T cells and macrophages correlates to longer overall survival in patients undergoing isolated hepatic perfusion for uveal melanoma liver metastasis.

作者信息

Johansson Junko, Siarov Jan, Kiffin Roberta, Mölne Johan, Mattsson Jan, Naredi Peter, Olofsson Bagge Roger, Martner Anna, Lindnér Per

机构信息

Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden.

出版信息

Oncoimmunology. 2020 Dec 10;9(1):1854519. doi: 10.1080/2162402X.2020.1854519.

DOI:10.1080/2162402X.2020.1854519
PMID:33344043
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7733984/
Abstract

Uveal melanoma is a malignant tumor of the eye that often metastasizes to the liver conferring poor prognosis. When comparing immune profiles in peripheral blood of untreated patients with uveal melanoma liver metastasis and healthy blood donors, it was observed that immune cells of uveal melanoma patients carried immunosuppressive features. Patient blood contained an increased content of CD14HLA-DR M-MDSCs and inflammatory CD16 monocytes, while their dendritic cells expressed lower levels of activation markers. Melanoma patients also harbored an enhanced fraction of CD4Foxp3 regulatory T cells, while their effector T cells expressed lower levels of the activation marker HLA-DR. Biopsies from liver metastases were obtained from patients with uveal melanoma that subsequently underwent hyperthermic isolated hepatic perfusion (IHP) with melphalan. There were trends indicating a positive correlation between a high infiltration of CD8 T cells in metastases and an activated immune cell profile in blood. High metastatic infiltration of CD8 T cells and CD68 macrophages, but not of immunosuppressive CD163 macrophages, correlated to a longer overall survival in patients treated with IHP. Hence, while the immune system of patients with uveal melanoma shows signs of immunosuppression, the presence of activated immune cells may correlate to a longer survival, at least following IHP treatment.

摘要

葡萄膜黑色素瘤是一种眼部恶性肿瘤,常转移至肝脏,预后较差。在比较未经治疗的葡萄膜黑色素瘤肝转移患者与健康献血者外周血中的免疫特征时,发现葡萄膜黑色素瘤患者的免疫细胞具有免疫抑制特性。患者血液中CD14HLA - DR M - MDSCs和炎性CD16单核细胞含量增加,而其树突状细胞表达的活化标志物水平较低。黑色素瘤患者还具有较高比例的CD4Foxp3调节性T细胞,而其效应T细胞表达的活化标志物HLA - DR水平较低。从接受美法仑热灌注隔离肝灌注(IHP)的葡萄膜黑色素瘤患者获取肝转移灶活检组织。有趋势表明转移灶中CD8 T细胞的高浸润与血液中活化免疫细胞谱呈正相关。CD8 T细胞和CD68巨噬细胞的高转移浸润,而非免疫抑制性CD163巨噬细胞的浸润,与接受IHP治疗患者的总生存期延长相关。因此,虽然葡萄膜黑色素瘤患者的免疫系统显示出免疫抑制迹象,但活化免疫细胞的存在可能与更长的生存期相关,至少在IHP治疗后如此。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa91/7733984/0fb5e0b5103d/KONI_A_1854519_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa91/7733984/91b4c224053a/KONI_A_1854519_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa91/7733984/3dc337e0ac4e/KONI_A_1854519_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa91/7733984/43d8b2d426a1/KONI_A_1854519_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa91/7733984/015eba1a964c/KONI_A_1854519_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa91/7733984/0fb5e0b5103d/KONI_A_1854519_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa91/7733984/91b4c224053a/KONI_A_1854519_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa91/7733984/3dc337e0ac4e/KONI_A_1854519_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa91/7733984/43d8b2d426a1/KONI_A_1854519_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa91/7733984/015eba1a964c/KONI_A_1854519_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa91/7733984/0fb5e0b5103d/KONI_A_1854519_F0005_OC.jpg

相似文献

1
Presence of tumor-infiltrating CD8 T cells and macrophages correlates to longer overall survival in patients undergoing isolated hepatic perfusion for uveal melanoma liver metastasis.肿瘤浸润性CD8 T细胞和巨噬细胞的存在与葡萄膜黑色素瘤肝转移患者接受孤立性肝灌注治疗后的总生存期延长相关。
Oncoimmunology. 2020 Dec 10;9(1):1854519. doi: 10.1080/2162402X.2020.1854519.
2
Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver.高剂量美法仑隔离肝灌注治疗局限于肝脏的葡萄膜黑色素瘤转移灶。
Melanoma Res. 2004 Feb;14(1):67-72. doi: 10.1097/00008390-200402000-00011.
3
Inflammatory cell infiltrates in advanced metastatic uveal melanoma.晚期转移性葡萄膜黑色素瘤中的炎性细胞浸润。
Hum Pathol. 2017 Aug;66:159-166. doi: 10.1016/j.humpath.2017.06.005. Epub 2017 Jun 24.
4
The immune cell landscape of metastatic uveal melanoma correlates with overall survival.转移性葡萄膜黑色素瘤的免疫细胞图谱与总生存期相关。
J Exp Clin Cancer Res. 2021 May 4;40(1):154. doi: 10.1186/s13046-021-01947-1.
5
Percutaneous Isolated Hepatic Perfusion as a Treatment for Isolated Hepatic Metastases of Uveal Melanoma: Patient Outcome and Safety in a Multi-centre Study.经皮孤立肝灌注治疗葡萄膜黑色素瘤孤立性肝转移:一项多中心研究的患者结局与安全性
Cardiovasc Intervent Radiol. 2017 Jun;40(6):864-872. doi: 10.1007/s00270-017-1588-2. Epub 2017 Jan 31.
6
Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial).孤立性肝灌注氨甲蝶呤治疗孤立性葡萄膜黑色素瘤肝转移患者:一项多中心、随机、开放标签、III 期试验(SCANDIUM 试验)。
J Clin Oncol. 2023 Jun 1;41(16):3042-3050. doi: 10.1200/JCO.22.01705. Epub 2023 Mar 20.
7
Isolated hepatic perfusion as a treatment for liver metastases of uveal melanoma.孤立性肝灌注治疗葡萄膜黑色素瘤肝转移
J Vis Exp. 2015 Jan 25(95):52490. doi: 10.3791/52490.
8
[Isolated liver perfusion with melphalan followed by pembrolizumab therapy for unresectable metastases of uveal melanoma to the liver].美法仑隔离肝灌注联合帕博利珠单抗治疗葡萄膜黑色素瘤不可切除性肝转移
Khirurgiia (Mosk). 2023(7):94-99. doi: 10.17116/hirurgia202307194.
9
MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.源自免疫赦免器官眼睛的MHC II类转导肿瘤细胞可启动并增强与原发性和转移性葡萄膜黑色素瘤细胞发生交叉反应的CD4(+) T淋巴细胞。
Cancer Res. 2007 May 1;67(9):4499-506. doi: 10.1158/0008-5472.CAN-06-3770.
10
Analysis of inflammatory cells in uveal melanoma after prior irradiation.分析既往放射治疗后葡萄膜黑色素瘤中的炎症细胞。
Invest Ophthalmol Vis Sci. 2013 Jan 14;54(1):360-9. doi: 10.1167/iovs.12-9424.

引用本文的文献

1
New insights on anti-tumor immunity of CD8 T cells: cancer stem cells, tumor immune microenvironment and immunotherapy.CD8 T细胞抗肿瘤免疫的新见解:癌症干细胞、肿瘤免疫微环境与免疫治疗
J Transl Med. 2025 Mar 17;23(1):341. doi: 10.1186/s12967-025-06291-y.
2
Tebentafusp, a T cell engager, promotes macrophage reprogramming and in combination with IL-2 overcomes macrophage immunosuppression in cancer.替贝伐单抗,一种T细胞衔接蛋白,可促进巨噬细胞重编程,并与白细胞介素-2联合使用,克服癌症中巨噬细胞的免疫抑制作用。
Nat Commun. 2025 Mar 10;16(1):2374. doi: 10.1038/s41467-025-57470-w.
3
The Current State of Systemic Therapy of Metastatic Uveal Melanoma.

本文引用的文献

1
Isolated limb perfusion with melphalan activates interferon-stimulated genes to induce tumor regression in patients with melanoma in-transit metastasis.用美法仑进行离体肢体灌注可激活干扰素刺激基因,从而诱导伴有皮肤转移的黑色素瘤患者的肿瘤消退。
Oncoimmunology. 2019 Nov 3;9(1):1684126. doi: 10.1080/2162402X.2019.1684126. eCollection 2020.
2
Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?葡萄膜黑色素瘤的免疫基础:免疫治疗是否有理论依据?
Cancers (Basel). 2019 Jul 26;11(8):1055. doi: 10.3390/cancers11081055.
3
Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis.
转移性葡萄膜黑色素瘤的系统治疗现状。
Am J Clin Dermatol. 2024 Sep;25(5):691-700. doi: 10.1007/s40257-024-00872-1. Epub 2024 Jun 22.
4
Construction of oxidative phosphorylation-related prognostic risk score model in uveal melanoma.葡萄膜黑色素瘤氧化磷酸化相关预后风险评分模型的构建。
BMC Ophthalmol. 2024 May 2;24(1):204. doi: 10.1186/s12886-024-03441-6.
5
Survival and Quality of Life after Isolated Hepatic Perfusion with Melphalan as a Treatment for Uveal Melanoma Liver Metastases - Final Results from the Phase III Randomized Controlled Trial SCANDIUM.美法仑隔离肝灌注治疗葡萄膜黑色素瘤肝转移后的生存情况和生活质量——III期随机对照试验SCANDIUM的最终结果
Ann Surg. 2024 Feb 29. doi: 10.1097/SLA.0000000000006255.
6
A gene mutation-based risk model for prognostic prediction in liver metastases.基于基因突变的肝转移预后预测风险模型。
BMC Genomics. 2023 Aug 26;24(1):489. doi: 10.1186/s12864-023-09595-9.
7
Immunohistochemical characterisation of the immune landscape in primary uveal melanoma and liver metastases.原发性葡萄膜黑色素瘤和肝转移灶中免疫景观的免疫组织化学特征。
Br J Cancer. 2023 Sep;129(5):772-781. doi: 10.1038/s41416-023-02331-w. Epub 2023 Jul 13.
8
Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial).孤立性肝灌注氨甲蝶呤治疗孤立性葡萄膜黑色素瘤肝转移患者:一项多中心、随机、开放标签、III 期试验(SCANDIUM 试验)。
J Clin Oncol. 2023 Jun 1;41(16):3042-3050. doi: 10.1200/JCO.22.01705. Epub 2023 Mar 20.
9
Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells.盖达西他滨通过控制 T 细胞、髓系来源的抑制细胞和 NK 细胞增加了体内抗 CTLA-4 和抗 PD-1 联合治疗对小鼠黑色素瘤的反应。
J Exp Clin Cancer Res. 2023 Mar 18;42(1):67. doi: 10.1186/s13046-023-02628-x.
10
Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial.美法仑经皮肝灌注联合伊匹木单抗加纳武单抗治疗晚期葡萄膜黑色素瘤:肖邦试验Ib期部分的首批安全性和有效性数据
Cardiovasc Intervent Radiol. 2023 Mar;46(3):350-359. doi: 10.1007/s00270-022-03338-1. Epub 2023 Jan 9.
转移性葡萄膜黑色素瘤治疗后的总生存:系统评价和荟萃分析。
Melanoma Res. 2019 Dec;29(6):561-568. doi: 10.1097/CMR.0000000000000575.
4
Isolated Limb Perfusion With Melphalan Triggers Immune Activation in Melanoma Patients.美法仑隔离肢体灌注引发黑色素瘤患者的免疫激活。
Front Oncol. 2018 Dec 3;8:570. doi: 10.3389/fonc.2018.00570. eCollection 2018.
5
Survival Rates in Patients After Treatment for Metastasis From Uveal Melanoma.葡萄膜黑色素瘤转移治疗后的患者生存率。
JAMA Ophthalmol. 2018 Sep 1;136(9):981-986. doi: 10.1001/jamaophthalmol.2018.2466.
6
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.纳武利尤单抗联合伊匹木单抗治疗晚期黑色素瘤的总生存期
N Engl J Med. 2017 Oct 5;377(14):1345-1356. doi: 10.1056/NEJMoa1709684. Epub 2017 Sep 11.
7
Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.程序性细胞死亡蛋白1或联合程序性死亡蛋白1/细胞毒性T淋巴细胞相关抗原4抑制治疗转移性葡萄膜黑色素瘤的预后因素及结局
Eur J Cancer. 2017 Sep;82:56-65. doi: 10.1016/j.ejca.2017.05.038. Epub 2017 Jun 22.
8
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.对10万个人类癌症基因组的分析揭示了肿瘤突变负荷的全貌。
Genome Med. 2017 Apr 19;9(1):34. doi: 10.1186/s13073-017-0424-2.
9
Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.使用PD-1和PD-L1抗体治疗转移性葡萄膜黑色素瘤的临床结果。
Cancer. 2016 Nov 15;122(21):3344-3353. doi: 10.1002/cncr.30258. Epub 2016 Aug 17.
10
Long-Term Follow-Up Evaluation of 68 Patients with Uveal Melanoma Liver Metastases Treated with Isolated Hepatic Perfusion.68例葡萄膜黑色素瘤肝转移患者接受孤立肝灌注治疗的长期随访评估
Ann Surg Oncol. 2016 Apr;23(4):1327-34. doi: 10.1245/s10434-015-4982-5. Epub 2015 Dec 1.